<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1301210415
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Steglatro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ERTUGLIFLOZIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        159
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Deutschland GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Merck Sharp & Dohme B.V
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10B
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Steglatro contains the active substance ertugliflozin.</p><p>&nbsp;</p><p>Steglatro is a member of a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors.</p><p>&nbsp;</p><p>What Steglatro is used for</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steglatro lowers blood sugar levels in adult patients (aged 18 years and older) with type 2 diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steglatro can be used alone or with some other medicines that lower blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to keep following your food and exercise plan while taking Steglatro.</p><p>&nbsp;</p><p>How Steglatro works</p><p>Ertugliflozin works by blocking the SGLT2 protein in your kidneys. This causes blood sugar to be removed in your urine.</p><p>&nbsp;</p><p>What is type 2 diabetes?</p><p>Type 2 diabetes is a condition in which your body does not make enough insulin or the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness and poor circulation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Steglatro</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ertugliflozin or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist, or nurse before and while taking Steglatro if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had yeast infections of the vagina or penis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had serious heart disease or if you have had a stroke.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have type 1 diabetes. Steglatro should not be used to treat this condition.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take other diabetes medicines; you are more likely to get low blood sugar with certain medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; might be at risk of dehydration (for example, if you are taking medicines that increase urine production [diuretics] or lower blood pressure or if you are over 65 years old). Ask about ways to prevent dehydration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat contact a doctor or the nearest hospital straight away. These symptoms could be a sign of &ldquo;diabetic ketoacidosis&rdquo; &ndash; a problem you can get with diabetes because of increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood, seen in tests. The risk of developing diabetic ketoacidosis may be increased with prolonged fasting, excessive alcohol consumption, dehydration, sudden reductions in insulin dose, or a higher need of insulin due to major surgery or serious illness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a lower limb amputation.</p><p>&nbsp;</p><p>It is important to check your feet regularly and adhere to any other advice regarding foot care and adequate hydration given by your healthcare professional. You should notify your doctor immediately if you notice any wounds or discolouration, or if you experience any tenderness or pain in your feet. Some studies indicate that taking ertugliflozin may have contributed to an increase in cases of lower limb amputation (mainly of the toe).</p><p>&nbsp;</p><p>Talk to your doctor immediately if you develop a combination of symptoms of pain, tenderness, redness, or swelling of the genitals or the area between the genitals and the anus with fever or feeling generally unwell. These symptoms could be a sign of a rare but serious or even life-threatening infection, called necrotising fasciitis of the perineum or Fournier&rsquo;s gangrene which destroys the tissue under the skin. Fournier&rsquo;s gangrene has to be treated immediately.</p><p>&nbsp;</p><p>When this medicine is used in combination with insulin or medicines that increase insulin release from the pancreas, low blood sugar (hypoglycaemia) can occur. Your doctor may reduce the dose of your insulin or other medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>Urine glucose</p><p>Because of how this medicine works, your urine will test positive for sugar (glucose) while you are on this medicine.</p><p>&nbsp;</p><p>Children and adolescents</p><p>Children and adolescents below 18 years should not take this medicine. It is not known if this medicine is safe and effective when used in children and adolescents under 18 years of age.</p><p>&nbsp;</p><p>Other medicines and Steglatro</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines which increase urine production (diuretics).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines that lower the sugar in your blood, such as insulin or medicines that increase insulin release from the pancreas.</p><p>If any of the above apply to you (or you are not sure), tell your doctor.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>It is not known if Steglatro can harm your unborn baby. If you are pregnant, talk with your doctor about the best way to control your blood sugar while you are pregnant. Do not use Steglatro if you are pregnant.</p><p>&nbsp;</p><p>It is not known if Steglatro passes into breast milk. Talk with your doctor about the best way to feed your baby if you take Steglatro. Do not use Steglatro if you are breast-feeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>This medicine has no or negligible influence on the ability to drive and use machines. Taking this medicine in combination with insulin or medicines that increase insulin release from the pancreas can cause blood sugar levels to drop too low (hypoglycaemia), which may cause symptoms such as shaking, sweating and change in vision, and may affect your ability to drive and use machines. Do not drive or use any tools or machines if you feel dizzy while taking Steglatro.</p><p>&nbsp;</p><p>Steglatro contains lactose</p><p>Steglatro contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p>Steglatro contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>How much to take</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose of Steglatro is one 5-mg tablet each day. Your doctor will decide whether to increase your dose to 15 mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will prescribe the right dose for you. Do not change your dose unless your doctor has told you to.</p><p>&nbsp;</p><p>Taking this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet; if you have difficulties with swallowing, the tablet can be broken or crushed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take one tablet every morning. Try to take it at the same time; this will help you remember to take it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your tablet with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to keep following your food and exercise plan while taking Steglatro.</p><p>&nbsp;</p><p>If you take more Steglatro than you should</p><p>If you take too much Steglatro, talk to a doctor or pharmacist straight away.</p><p>&nbsp;</p><p>If you forget to take Steglatro</p><p>If you forget a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and go back to your regular schedule.</p><p>&nbsp;</p><p>Do not take a double dose (two doses on the same day) to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Steglatro</p><p>Do not stop taking this medicine without talking to your doctor. Your blood sugar levels may increase if you stop the medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Contact a doctor or the nearest hospital straight away if you have any of the following serious side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Diabetic ketoacidosis (rare, may affect up to </strong><strong>1 in 1,000 people)</strong></p><p><strong>&nbsp;</strong></p><p>These are the signs of diabetic ketoacidosis (see also section &ldquo;Warnings and precautions&rdquo;):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of &ldquo;ketone bodies&rdquo; in your urine or blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick or being sick</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast and deep breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual sleepiness or tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat</p><p>This may occur regardless of blood glucose level. Your doctor may decide to temporarily or permanently stop your treatment with Steglatro.</p><p>&nbsp;</p><p>If you notice any of the side effects above, contact a doctor or the nearest hospital straight away.</p><p>&nbsp;</p><p>Contact your doctor as soon as possible if you notice the following side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Dehydration (losing too much water from your body; common, may affect up to </strong><strong>1 in 10 people)</strong></p><p>Symptoms of dehydration include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, light-headed, or weak, especially when you stand up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>&nbsp;</p><p>You may be more likely to get dehydrated if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take medicines that increase your urine production (diuretics) or lower blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are 65 years or older</p><p>&nbsp;</p><p>Low blood sugar (hypoglycaemia; common)</p><p>Your doctor will tell you how to treat low blood sugar and what to do if you have any of the symptoms or signs below. The doctor may lower the dose of your insulin or other diabetes medicine.</p><p>&nbsp;</p><p>Signs and symptoms of low blood sugar may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hunger</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling jittery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>&nbsp;</p><p>If you notice any of the side effects above, contact your doctor as soon as possible.</p><p>&nbsp;</p><p>Other side effects when taking Steglatro: Very common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal yeast infection (thrush)</p><p>&nbsp;</p><p>Common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yeast infections of the penis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in urination, including urgent need to urinate more often, in larger amounts, or at night</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thirst</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vaginal itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of urea in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of total and bad cholesterol (called LDL - a type of fat in your blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes in the amount of red blood cells in your blood (called haemoglobin)</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show changes related to kidney function (such as &lsquo;creatinine&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful urination</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &nbsp;National Pharmacovigilance and Drug Safety Centre (NPC). SFDA By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP.</p><p>Store below 30&deg;C.&nbsp; Store in the original package</p><p>&nbsp;</p><p>&nbsp;</p><p>Do not use this medicine if the packaging is damaged or shows signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Steglatro contains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is ertugliflozin.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Steglatro 5 mg film-coated tablet contains 5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid).</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each Steglatro 15 mg film-coated tablet contains 15 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core: microcrystalline cellulose (E460), lactose monohydrate (see section 2), sodium starch glycolate (Type A), magnesium stearate (E470b).</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film coating: hypromellose 2910/6 (E464), lactose monohydrate (see section 2), macrogol 3350 (E1521), triacetin (E1518), titanium dioxide (E171), iron oxide red (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Steglatro 5 mg film-coated tablets (tablets) are pink, 6.4 x 6.6 mm, triangular-shaped, with “701” on one side and plain on the other side.
•	Steglatro 15 mg film-coated tablets (tablets) are red, 9.0 x 9.4 mm, triangular-shaped, with “702” on one side and plain on the other side.

Steglatro is available in Alu/PVC/PA/Alu blisters. The pack sizes are 14, 28, 30, 84, 90 and 98 film- coated tablets in non-perforated blisters and 30x1 film-coated tablets in perforated unit dose blisters.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Pfizer Manufacturing Deutschland GmbH</p><p>Betriebsstatte, Freiburg</p><p>Mooswaldellee 1</p><p>79090</p><p>Freiburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised in July 2020


To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health
Ministers Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما ستيقلاترو </strong><br />يحتوي ستيقلاترو على المادة الفعّالة إرتوقليفلوزين.</p><p dir="RTL">ينتمي ستيقلاترو إلى مجموعة من الأدوية تُسمّى مثبطات الناقل المشارك للصوديوم/جلوكوز-2 (SGLT2) .</p><p dir="RTL"><strong>دواعي استخدام</strong> <strong>ستيقلاترو </strong></p><p dir="RTL">&bull; يقلل ستيقلاترو من مستويات السكر في الدم لدى المرضى البالغين (الذين تتراوح أعمارهم بين 18 سنة &nbsp;وما فوق) المصابين بمرض السكري من النوع 2.</p><p dir="RTL">&bull; يمكن استخدام ستيقلاترو بمفرده أو مع بعض الأدوية الأخرى التي تُخفض نسبة السكر في الدم.</p><p dir="RTL">&bull; تحتاج إلى الاستمرار في الالتزام بخطة الغذاء والتمارين أثناء تناول ستيقلاترو.</p><p dir="RTL"><br /><strong>طريقة عمل ستيقلاترو </strong></p><p dir="RTL">يعمل إرتوقليفلوزين عن طريق تثبيط عمل بروتين SGLT2 في الكليتين، مما يؤدي إلى طرح سكّر الدم في البول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما مرض السكري من النوع 2</strong></p><p dir="RTL">مرض السكري من النوع الثاني هو حالة مرضية يصبح فيها جسمك غير قادر على إنتاج كمية كافية من الأنسولين أو أنّ الأنسولين الذي ينتجه الجسم لا يعمل كما يجب. يمكن أن يقوم جسمك أيضًا بإنتاج الكثير من السكر. عندما يحدث هذا، يتراكم السكر (الجلوكوز) في الدم مما قد يؤدي إلى مشاكل طبية خطيرة، مثل أمراض القلب وأمراض الكلى والعمى وضعف الدورة الدموية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ستيقلاترو </strong><br />&bull; إذا كنت تعاني من حساسية تجاه إرتوقليفلوزين أو تجاه أيّ من المكونات الأخرى لهذا الدواء (المذكورة في الفقرة رقم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرض قبل وأثناء استخدام ستيقلاترو<strong> </strong>إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى.</p><p dir="RTL">&bull; تعاني أو سبق وعانيت من عدوى فطريّة في المهبل أو القضيب.</p><p dir="RTL">&bull; سبق وأن عانيت من مرض خطير في القلب أو أُصبت بسكتة دماغية.</p><p dir="RTL">&bull; تعاني من مرض السكري من النوع 1 ، &nbsp;يجب عدم استخدام ستيقلاترو لعلاج هذه الحالة.</p><p dir="RTL">&bull; تتناول أدوية أخرى لعلاج مرض السكري؛ إذ قد يزداد احتمال انخفاض نسبة السكر في الدم لديك عند استخدام ستيقلاترو مع بعض الأدوية الأخرى.</p><p dir="RTL">&bull; مُعرّض لخطر حدوث الجفاف (على سبيل المثال، إذا كنت تتناول أدوية تزيد من إنتاج البول [مدرات البول] أو أدوية لعلاج ضغط الدم المُرتفع أو إذا كان عمرك يزيد عن 65 عامًا). اسأل طبيبك عن طرق تجنّب حدوث الجفاف.</p><p dir="RTL">&bull; تتعرض لفقدان الوزن السريع، والشعور بالمرض أو حدوث المرض، وألم البطن، والعطش الشديد، والتنفس السريع و العميق، والارتباك، والنعاس أو التعب غير العادي، وظهور رائحة حلوة لنَفَسِك (رائحة الفاكهة)؛ أو الإحساس بطعم حلو أو معدني في فمك أو تغيّر رائحة البول أو العرَق لديك، راجع طبيبك أو أقرب مستشفى على الفور. قد تكون هذه الأعراض علامة على حدوث &quot;الحُماض الكيتوني السكري&quot; - وهي مشكلة يمكن أن تحدث بسبب مرض السكري نتيجة زيادة مستويات &quot;الأجسام الكيتونيّة&quot; في البول أو الدم، والتي تظهر في الفحوصات. قد يزداد خطر الإصابة بالحماض الكيتوني السكّري مع الصيام لفترات طويلة، والإفراط في استهلاك الكحول، والجفاف، والتخفيض المفاجئ في جرعة الأنسولين، أو مع الحاجة لكميات أعلى من الأنسولين بسبب الخضوع لجراحة كبرى أو التعرّض لمرض خطير.</p><p dir="RTL">&bull; بتر في الطرف السفلي.</p><p>Arabic translation.&nbsp;</p><p dir="RTL">من المهم فحص قدميك بانتظام والالتزام بأي نصيحة أخرى تتعلق برعاية القدم والترطيب الكافي الذي يمنحه أخصائي الرعاية الصحية. يجب عليك إخطار طبيبك على الفور إذا لاحظت أي جروح أو تغير اللون، أو إذا كنت تعاني من أي ألم في قدميك. تشير بعض الدراسات إلى أن تناول إرتوقليفلوزين قد يكون ساهم في زيادة حالات بتر الأطراف السفلية بشكل رئيسي من إصبع القدم. تحدث إلى طبيبك على الفور إذا كنت تعاني من الألم أو أو الاحمرار أو تورم الأعضاء التناسلية أو المنطقة الواقعة بين الأعضاء التناسلية والإصابة بالحمى أو الشعور بتوعك عام. يمكن أن تكون هذه الأعراض علامة على عدوى نادرة ولكنها خطيرة أو حتى مهددة للحياة، تسمى غرغرينا فورنييه التي تدمر الأنسجة تحت الجلد. غرغرينا فورنييه يجب أن تعالج على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يحدث انخفاض في نسبة السكر في الدم (نقص سكر الدم)عند استخدام هذا الدواء بالاشتراك مع الأنسولين أو الأدوية التي تُحفّز إفراز الأنسولين من البنكرياس. قد يقلل الطبيب لك جرعة الأنسولين أو أي دواء آخر تتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>سكّر البول </strong></p><p dir="RTL">سيُظهر فحص البول لديك نتيجة إيجابيّة لوجود السكر أثناء تناولك لهذا الدواء، وذلك بسبب الطريقة التي يعمل بها ستيغلاترو.<strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب على الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا عدم تناول هذا الدواء. إذ من غير المعروف&nbsp; إذا كان هذا الدواء آمنًا وفعالًا عند استخدامه لدى هذه الفئة العُمريّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام أدوية أخرى مع </strong><strong>ستيقلاترو </strong><strong>&nbsp;</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرا أو قد تتناول أيّ أدوية أخرى.<br />أخبر طبيبك على وجه الخصوص إذا كنت تتناول:</p><p dir="RTL">&bull; أدوية تزيد من إنتاج البول (مُدرّات البول).</p><p dir="RTL">&bull; أدوية أخرى تُقلل من كمية السكر في الدم، مثل الأنسولين أو الأدوية التي تُحفّز إفراز الأنسولين من البنكرياس.</p><p dir="RTL">أخبر طبيبك إذا كان أيّ مما سبق ينطبق عليك (أو إذا لم تكن متأكدًا).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مُرضعًا ، أو تعتقدين أنّك قد تكونين حاملًا ، أو تخططين لإنجاب طفل، فعليك استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">من غير المعروف إذا كان ستيقلاترو يضر بجنينك. إذا كنت حاملًا ، استشيري طبيبك حول أفضل طريقة للتحكم في نسبة السكر في الدم أثناء الحمل. لا تستخدمي ستيقلاترو إذا كنتِ حاملًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف إذا كان هذا الدواء يُفرز في حليب الثدي. استشيرى طبيبك حول أفضل طريقة لتغذية &nbsp;طفلك الرضيع إذا كنتِ تتناولين ستيغلاترو. يجب عليك عدم استخدام هذا الدواء إذا كنت ترضعين رضاعة طبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">هذا الدواء ليس له تأثير يُذكر على القدرة على القيادة واستخدام الآلات. يمكن أن يؤدي تناول هذا الدواء إلى جانب الأنسولين أو الأدوية التي تزيد من إفراز الأنسولين من البنكرياس إلى انخفاض شديد في مستويات السكر في الدم (نقص سكر الدم)، مما قد يتسبب في أعراض مثل الارتعاش والتعرق وتغيرات في الرؤية مما قد يؤثر على قدرتك على القيادة واستخدام الآلات. تجنّب القيادة أو استخدام أيّ أدوات أو آلات إذا شعرت بالدوار أثناء تناول ستيغلاترو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض محتويات </strong><strong>ستيقلاترو</strong><br /><strong>ستيقلاترو يحتوي على اللاكتوز</strong><br />يحتوي ستيقلاترو على اللاكتوز (سكر الحليب). إذا أخبرك طبيبك في السابق بأن لديك حساسية تجاه بعض السكّريات، فراجع طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ستيقلاترو يحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الصوديوم</strong></p><p dir="RTL">&nbsp;يحتوي هذا الدواء على أقل من 1 مليمول صوديوم 23 ملغ لكل قرص ، أي &quot;خالي من الصوديوم.</p><p dir="RTL">.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء حسب ارشادات الطبيب أو الصيدلي تمامًا. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.<br />&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">&bull; الجرعة الأولية من ستيقلاترو هي حبة واحدة &quot;5 ملغم<strong> </strong>&quot; مرة واحدة في اليوم. سوف يقرر الطبيب زيادة الجرعة إلى 15 ملغم<strong> </strong>إذا تطلّب الأمر.</p><p dir="RTL">&bull; سيصف لك الطبيب الجرعة المناسبة. لا تُغيّر الجرعة إلا إذا أخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناول الدواء</strong></p><p dir="RTL">&bull; قم بابتلاع القرص كاملًا ؛ إذا كنت تواجه صعوبة في ابتلاع القرص ، فيمكنك كسره أو سحقه.</p><p dir="RTL">&bull; تناول قرص واحد كل صباح. حاول أن تتناوله في نفس الوقت من كلّ يوم ؛ سيساعدك ذلك على تذكر موعد الجرعة.</p><p dir="RTL">&bull; يمكنك أن تتناول القرص مع أو بدون طعام.</p><p dir="RTL">&bull; تحتاج إلى الاستمرار في اتباع خطة الغذاء والتمارين أثناء تناول ستيقلاترو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت من ستيقلاترو أكثر مما يجب </strong></p><p dir="RTL">إذا تناولت من ستيقلاترو أكثر مما يجب ، تحدث إلى الطبيب أو الصيدلي على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تتناول إحدى جرعات ستيقلاترو &nbsp;&nbsp;</strong></p><p dir="RTL">إذا نسيت أن تتناول إحدى الجرعات، خذها حالما تتذكرها. ولكن، إذا كان الوقت قد حان لتناول جرعتك التالية ، فتجاوز الجرعة الفائتة وعد إلى جدولك المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة (جرعتان في نفس اليوم) للتعويض عن جرعة منسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول ستيقلاترو &nbsp;</strong><br />لا تتوقف عن تناول هذا الدواء دون استشارة طبيبك. قد تزيد مستويات السكر في الدم إذا توقفت عن تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يُسبب هذا الدواء أعراضًا جانبيّة وإن كانت لا تحدث لدى جميع من يتناوله.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>توقّف عن تناول ستيقلاترو وراجع الطبيب على الفور إذا لاحظت أي</strong><strong>ًّا</strong><strong> من الأعراض الجانبية الخطرة التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحماض الكيتوني السكري (نادر، قد يؤثر على 1 من بين 1،000 شخص)</strong></p><p dir="RTL">الأعراض التالية تُمثل علامات الحماض الكيتوني السكري (انظر أيضا فقرة &quot;التحذيرات والاحتياطات&quot;):</p><p dir="RTL">&bull; زيادة مستويات &quot;الأجسام الكيتونيّة&quot; في البول أو الدم</p><p dir="RTL">&bull; فقدان الوزن السريع</p><p dir="RTL">&bull; الغثيان أو التقيؤ</p><p dir="RTL">&bull; ألم البطن</p><p dir="RTL">&bull; العطش الشديد</p><p dir="RTL">&bull; تنفس سريع وعميق</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; النعاس أو التعب غير المعتاد &nbsp;</p><p dir="RTL">&bull; رائحة حلوة لنَفَسِك (رائحة الفواكه)، وطعم حلو أو معدني في فمك أو تغيّر رائحة البول أو العرق لديك.</p><p dir="RTL">قد يحدث هذا بغض النظر عن مستوى السكر في الدم. قد يقرر طبيبك إيقاف علاجك بستيقلاترو بشكل مؤقت أو دائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه، راجع الطبيب أو أقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بالطبيب في أقرب وقت ممكن إذا تعرّضت للأعراض الجانبية التالية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجفاف (فقدان كمية كبيرة من الماء من جسمك؛ شائع، قد يؤثر على 1 من بين 10 أشخاص)</strong></p><p dir="RTL">تشمل أعراض الجفاف ما يلي:</p><p dir="RTL">&bull; جفاف الفم</p><p dir="RTL">&bull; الشعور بالدوار، أو الدوخة، أو الضعف، خاصة عند الوقوف</p><p dir="RTL">&bull; الإغماء</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون أكثر عرضة للإصابة بالجفاف إذا كنت:</p><p dir="RTL">&bull; تعاني من مشاكل في الكلى</p><p dir="RTL">&bull; تتناول الأدوية التي تزيد من إنتاج البول (مُدرّات البول) أو تلك الخافضة لضغط الدم</p><p dir="RTL">&bull; تبلغ 65 سنة من العمر أو أكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انخفاض نسبة السكر في الدم (نقص سكر الدم ؛ شائع)</strong></p><p dir="RTL">سيخبرك الطبيب عن كيفية علاج انخفاض سكر الدم وماذا تفعل إذا كان لديك أي من الأعراض أو العلامات أدناه. قد يقلل الطبيب من جرعة الأنسولين أو أي دواء آخر مضاد للسكري تستخدمه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تشمل علامات وأعراض انخفاض نسبة السكر في الدم ما يلي:</p><p dir="RTL">&bull; الصداع</p><p dir="RTL">&bull; النعاس</p><p dir="RTL">&bull; الهيجان</p><p dir="RTL">&bull; الجوع</p><p dir="RTL">&bull; الدوخة</p><p dir="RTL">&bull; الارتباك</p><p dir="RTL">&bull; التعرق</p><p dir="RTL">&bull; الشعور بالتوتر الشديد</p><p dir="RTL">&bull; الشعور بالضعف</p><p dir="RTL">&bull; تسارع نبضات القلب</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه ، راجع طبيبك في أسرع وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وتشمل الأعراض الجانبية الأخرى: </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا</strong></p><p dir="RTL">&bull; عدوى الفطريات المهبلية (القلاع)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong></p><p dir="RTL">&bull; عدوى الفطريات في القضيب</p><p dir="RTL">&bull; التغيرات في التبول ، بما في ذلك الحاجة المُلحّة إلى التبول المُتكرّر، بكميات أكبر، أو في الليل</p><p dir="RTL">&bull; العطش</p><p dir="RTL">&bull; الحكة المهبلية</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية اليوريا في دمك</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية الكولسترول الكلّي والسيئ (تسمى LDL - نوع من الدهون في دمك)</p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغيرات في كمية كريات الدم الحمراء في الدم (تسمى الهيموغلوبين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تُؤثر على شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">&bull; قد تُظهر فحوصات الدم تغييرات متعلقة بوظائف الكلى (مثل &quot;كرياتينين&quot;)</p><p dir="RTL">&bull; ألم أثناء التبوّل</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبيّة</strong><br />إذا أُصبت بأيّ أعراض جانبية، تحدث مع طبيبك أو الصيدلي أو الممرض. يتضمن ذلك أيّ أعراض جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot;. يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء من خلال الإبلاغ عن الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على شريط الألومنيوم والكرتون بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية. يُحفظ في العبوة الأصلية .</p><p dir="RTL">لا تستخدم هذا الدواء إذا كانت العبوة تالفة أو تظهر عليها علامات الفتح.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات ستيقلاترو </strong></p><p dir="RTL">&bull; المادة الفعالة هي إرتوقليفلوزين &nbsp;</p><p dir="RTL">o يحتوي كل قرص من أقراص ستيقلاترو المُغلّف تركيزه 5 ملغم<strong> </strong>على 5 ملغم<strong> </strong>من إرتوقليفلوزين (على شكل إرتوقليفلوزين إل-بيروجلوتاميك أسيد)<br />o يحتوي كل قرص من أقراص ستيقلاترو المُغلّف تركيزه 15 ملغم<strong> </strong>على 15 ملغم<strong> </strong>من إرتوقليفلوزين (على شكل إرتوقليفلوزين إل-بيروجلوتاميك أسيد)</p><p dir="RTL">&bull; المكونات الأخرى هي:</p><p dir="RTL">o لبّ القرص: السليلوز دقيق التبلور (E460)، لاكتوز مونوهيدرات (أنظر الفقرة 2)، جليكولات النشا الصودي (النوع أ)، ستيرات المغنيسيوم (E470b).</p><p dir="RTL">o طبقة الغشاء الرقيق: هيبروميلوز 2910/6 &nbsp;(E464)، لاكتوز مونوهيدرات (أنظر الفقرة 2)، &nbsp;ماكروجول 3350 (E1521)، ترياسيتين (E1518)، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172)،.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما الشكل الصيدلاني لستيقلاترو ووصفه وحجم عبوته</strong><br />&bull; أقراص ستيقلاترو 5 ملغم<strong> </strong>هي أقراص لونها ورديّ، يبلغ حجمها 6.4&times; 6.6 مم، مُثلّثة الشكل، منقوش على أحد جانبيها فقط الرقم &nbsp;&quot;701&quot; .</p><p dir="RTL">&bull; أقراص ستيقلاترو 15 ملغم<strong> </strong>هي أقراص لونها أحمر، يبلغ حجمها 9.0 &times;&nbsp; 9.4 مم، مُثلّثة الشكل، منقوش على أحد جانبيها فقط الرقم&nbsp; &quot;702&quot; .</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر ستيقلاترو في شرائط من الألومنيوم مصنوعة من Alu / PVC / PA / Alu. تتضمن أحجام العبوات 14 و 28 و 30 و 84 و 90 و 98 قرص مُغلف بغشاء رقيق على شكل شرائط من الألومنيوم غير مُثقبة وعبوات تحتوي على 30 &times; 1 قرص على شكل شريط من الألومنيوم المُثقّبة المُحددة الجرعة.</p><p dir="RTL"><strong>قد لا يتم تسويق جميع أحجام العبوات.</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق :</strong></p><p dir="RTL">ميرك شارب و دوم بي. في.</p><p dir="RTL">واردرويج</p><p dir="RTL">٢٠٣١ بي ان هارلم</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">شركة فايزر التصنيع دويتشلاند جي إم بي إتش</p><p dir="RTL">&nbsp;بيتريبستاتي، فرايبورغ</p><p dir="RTL">&nbsp;موسوالديلي 1</p><p dir="RTL">&nbsp;79090</p><p>&nbsp;فرايبورغ، ألماني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            لقد تمت مراجعة هذه النشرة بتاريخ يوليو 2020

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.

	
(إن هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
تمت الموافقة على نشرة المعلومات الخاصة بالمريض من قبل الهيئة العامة للغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Steglatro 5 mg film-coated tablets Steglatro 15 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Steglatro 5 mg film-coated tablets
Each tablet contains 5 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid).

Excipient(s) with known effect
Each tablet contains 28 mg of lactose (as monohydrate).

Steglatro 15 mg film-coated tablets
Each tablet contains 15 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid).

Excipient(s) with known effect
Each tablet contains 85 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet). Steglatro 5 mg film-coated tablets
Pink, 6.4 x 6.6 mm, triangular-shaped, film-coated tablets debossed with “701” on one side and plain
on the other side.

Steglatro 15 mg film-coated tablets
Red, 9.0 x 9.4 mm, triangular-shaped, film-coated tablets debossed with “702” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in addition to other medicinal products for the treatment of diabetes.</p><p>&nbsp;</p><p>(For study results with respect to combinations and effects on glycaemic control see sections 4.4, 4.5, and 5.1.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Posology</u></p><p>The recommended starting dose of ertugliflozin is 5 mg once daily. In patients tolerating ertugliflozin 5 mg once daily, the dose can be increased to 15 mg once daily if additional glycaemic control is needed.</p><p>&nbsp;</p><p>When ertugliflozin is used in combination with insulin or an insulin secretagogue, a lower dose of insulin or the insulin secretagogue may be required to reduce the risk of hypoglycaemia (see sections 4.4, 4.5, and 4.8).</p><p>&nbsp;</p><p>In patients with volume depletion, correcting this condition prior to initiation of ertugliflozin is recommended (see section 4.4).</p><p>&nbsp;</p><p>If a dose is missed, it should be taken as soon as the patient remembers. Patients should not take two doses of Steglatro on the same day.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Renal </em><em>impairment</em></p><p>Assessment of renal function is recommended prior to initiation of Steglatro and periodically thereafter (see section 4.4).</p><p>&nbsp;</p><p>Initiation of this medicinal product is not recommended in patients with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2&nbsp;or CrCl less than 60 ml/min (see section 4.4).</p><p>Steglatro should be discontinued when eGFR is persistently less than 45 ml/min/1.73 m2&nbsp;or CrCl is persistently less than 45 ml/min.</p><p>&nbsp;</p><p>Steglatro should not be used in patients with severe renal impairment, with end-stage renal disease (ESRD), or receiving dialysis, as it is not expected to be effective in these patients.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>No dose adjustment of ertugliflozin is necessary in patients with mild or moderate hepatic impairment. Ertugliflozin has not been studied in patients with severe hepatic impairment and is not recommended for use in these patients (see section 5.2).</p><p>&nbsp;</p><p><em>Elderly (&ge; 65 years old)</em></p><p>No dose adjustment of ertugliflozin is recommended based on age. Renal function and risk of volume depletion should be taken into account (see sections 4.4 and 4.8). There is limited experience with Steglatro in patients &ge; 75 years of age.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of ertugliflozin in children under 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Steglatro should be taken orally once daily in the morning, with or without food. In case of swallowing difficulties, the tablet could be broken or crushed as it is an immediate-release dosage form.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Steglatro should not be used in patients with type 1 diabetes mellitus.</p><p>&nbsp;</p><p><u>Hypotension/Volume depletion</u></p><p>Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating Steglatro (see section 4.8), particularly in patients with impaired renal function (eGFR less than 60 ml/min/1.73 m<sup>2</sup> or CrCl less than</p><p>60 ml/min), elderly patients (&ge; 65 years), patients on diuretics, or patients on anti-hypertensive therapy with a history of hypotension. Before initiating Steglatro, volume status should be assessed and corrected if indicated. Monitor for signs and symptoms after initiating therapy.</p><p>&nbsp;</p><p>Due to its mechanism of action, ertugliflozin induces an osmotic diuresis and increases serum creatinine and decreases eGFR. Increases in serum creatinine and decreases in eGFR were greater in patients with moderate renal impairment (see section 4.8).</p><p>&nbsp;</p><p>In case of conditions that may lead to fluid loss (e.g., gastrointestinal illness), careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving ertugliflozin. Temporary interruption of treatment with ertugliflozin should be considered until the fluid loss is corrected.</p><p>&nbsp;</p><p><u>Diabetic ketoacidosis</u></p><p>Rare cases of DKA, including life-threatening and fatal cases, have been reported in clinical trials and post-marketing in patients treated with sodium glucose co-transporter-2 (SGLT2) inhibitors, and cases have been reported in clinical trials with ertugliflozin. In a number of cases, the presentation of the condition was atypical with only moderately increased blood glucose values, below 14 mmol/l</p><p>(250 mg/dl). It is not known if DKA is more likely to occur with higher doses of ertugliflozin.</p><p>&nbsp;</p><p>The risk of diabetic ketoacidosis must be considered in the event of non-specific symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.</p><p>&nbsp;</p><p>In patients where DKA is suspected or diagnosed, treatment with ertugliflozin should be discontinued immediately.</p><p>&nbsp;</p><p>Treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. Monitoring of ketones is recommended in these patients. Measurement of blood ketone levels is preferred to urine. Treatment with ertugliflozin may be restarted when the ketone values are normal and the patient&rsquo;s condition has stabilised.</p><p>&nbsp;</p><p>Before initiating ertugliflozin, factors in the patient history that may predispose to ketoacidosis should be considered.</p><p>&nbsp;</p><p>Patients who may be at higher risk of DKA include patients with a low beta-cell function reserve (e.g., type 2 diabetes patients with low C-peptide or latent autoimmune diabetes in adults (LADA) or patients with a history of pancreatitis), patients with conditions that lead to restricted food intake or severe dehydration, patients for whom insulin doses are reduced and patients with increased insulin requirements due to acute medical illness, surgery, or alcohol abuse. SGLT2 inhibitors should be used with caution in these patients.</p><p>&nbsp;</p><p>Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.</p><p>&nbsp;</p><p>The safety and efficacy of ertugliflozin in patients with type 1 diabetes have not been established and ertugliflozin should not be used for treatment of patients with type 1 diabetes. Limited data from</p><p>&nbsp;</p><p>clinical trials suggest that DKA occurs with common frequency when patients with type 1 diabetes are treated with SGLT2 inhibitors.</p><p>&nbsp;</p><p><u>Lower limb amputations</u></p><p>In an ongoing clinical study of ertugliflozin added to existing therapy in type 2 diabetes patients with a history of established cardiovascular disease, an approximately 1.2-1.6-fold increase in cases of lower limb amputation (primarily of the toe) has been observed in patients treated with ertugliflozin. An increase in cases of lower limb amputation (primarily of the toe) has also been observed in long-term clinical studies with another SGLT2 inhibitor. As an underlying mechanism has not been established, risk factors, apart from general risk factors, for amputation are unknown.</p><p>&nbsp;</p><p>Before initiating ertugliflozin, consider factors in the patient history that may increase the risk for amputation. As precautionary measures, consideration should be given to carefully monitoring patients with a higher risk for amputation events and counselling patients about the importance of routine preventative foot care and maintaining adequate hydration. Consideration may also be given to stopping treatment with ertugliflozin in patients who develop events which may precede amputation such as lower-extremity skin ulcer, infection, osteomyelitis or gangrene.</p><p>&nbsp;</p><p><u>Impairment in renal function</u></p><p>The efficacy of ertugliflozin is dependent on renal function, and efficacy is reduced in patients who have moderate renal impairment and likely absent in patients with severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>Steglatro should not be initiated in patients with an eGFR below 60 ml/min/1.73 m<sup>2</sup> or CrCl below 60 ml/min. Steglatro should be discontinued when eGFR is persistently below 45 ml/min/1.73 m<sup>2</sup> or CrCl is persistently below 45 ml/min due to a reduction of efficacy.</p><p>&nbsp;</p><p>Monitoring of renal function is recommended as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prior to ertugliflozin initiation and periodically during treatment (see section 4.2).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; More frequently in patients with an eGFR below 60 ml/min/1.73 m<sup>2</sup> or a CrCl below 60 ml/min.</p><p>&nbsp;</p><p><u>Hypoglycaemia with concomitant use with insulin and insulin secretagogues</u></p><p>Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue, which are known to cause hypoglycaemia (see section 4.8). Therefore, a lower dose of insulin or insulin secretagogue may be required to minimise the risk of hypoglycaemia when used in combination with ertugliflozin (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p><u>Genital mycotic infections</u></p><p>Ertugliflozin increases the risk of genital mycotic infections. In trials with SGLT2 inhibitors, patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections (see section 4.8). Patients should be monitored and treated appropriately.</p><p>&nbsp;</p><p><u>Urinary tract infections</u></p><p>Urinary glucose excretion may be associated with an increased risk of urinary tract infections. The incidence of urinary tract infections was not notably different in the ertugliflozin 5 mg and 15 mg groups (4.0% and 4.1%) and the placebo group (3.9%). Most of the events were mild or moderate and no serious case was reported. Temporary interruption of ertugliflozin should be considered when treating pyelonephritis or urosepsis.</p><p>&nbsp;</p><p><u>Necrotising fasciitis of the perineum (Fournier&rsquo;s gangrene)</u></p><p>Post-marketing cases of necrotising fasciitis of the perineum, (also known as Fournier&rsquo;s gangrene), have been reported in female and male patients taking SGLT2 inhibitors. This is a rare but serious and potentially life-threatening event that requires urgent surgical intervention and antibiotic treatment.</p><p>&nbsp;</p><p>Patients should be advised to seek medical attention if they experience a combination of symptoms of pain, tenderness, erythema, or swelling in the genital or perineal area, with fever or malaise. Be aware that either uro-genital infection or perineal abscess may precede necrotising fasciitis. If Fournier&rsquo;s</p><p>&nbsp;</p><p>gangrene is suspected, Steglatro should be discontinued and prompt treatment (including antibiotics and surgical debridement) should be instituted.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>Elderly patients may be at an increased risk of volume depletion. Patients 65 years and older treated with ertugliflozin had a higher incidence of adverse reactions related to volume depletion compared to younger patients. Ertugliflozin is expected to have diminished efficacy in elderly patients with renal impairment (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p><u>Cardiac failure</u></p><p>Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with ertugliflozin in NYHA class III-IV.</p><p>&nbsp;</p><p><u>Urine laboratory assessments</u></p><p>Due to its mechanism of action, patients taking Steglatro will test positive for glucose in their urine. Alternative methods should be used to monitor glycaemic control.</p><p>&nbsp;</p><p><u>Interference with 1,5-anhydroglucitol (1,5-AG) assay</u></p><p>Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking SGLT2 inhibitors. Alternative methods should be used to monitor glycaemic control.</p><p>&nbsp;</p><p><u>Lactose</u></p><p>The tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p>&nbsp;</p><p><em><u>Diuretics</u></em></p><p>Ertugliflozin may add to the diuretic effect of diuretics and may increase the risk of dehydration and hypotension (see section 4.4).</p><p>&nbsp;</p><p><em><u>Insulin and insulin secretagogues</u></em></p><p>Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with ertugliflozin (see sections 4.2, 4.4, and 4.8).</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p>&nbsp;</p><p><em><u>Effects of other medicinal products on the pharmacokinetics of ertugliflozin</u></em></p><p>Metabolism by UGT1A9 and UGT2B7 is the primary clearance mechanism for ertugliflozin.</p><p>&nbsp;</p><p>Interaction studies conducted in healthy subjects, using a single dose design, suggest that the pharmacokinetics of ertugliflozin are not altered by sitagliptin, metformin, glimepiride, or simvastatin.</p><p>&nbsp;</p><p>Multiple-dose administration of rifampin (a UGT and CYP inducer) decreases ertugliflozin AUC and Cmax&nbsp;by 39% and 15%, respectively. This decrease in exposure is not considered clinically relevant and therefore, no dose adjustment is recommended. A clinically relevant effect with other inducers (e.g., carbamazepine, phenytoin, phenobarbital) is not expected.</p><p>&nbsp;</p><p>The impact of UGT inhibitors on the pharmacokinetics of ertugliflozin has not been studied clinically, but potential increase in ertugliflozin exposure due to UGT inhibition is not considered to be clinically relevant.</p><p>&nbsp;</p><p><em><u>Effects of ertugliflozin on the pharmacokinetics of other medicinal products</u></em></p><p>Interaction studies conducted in healthy volunteers suggest that ertugliflozin had no clinically relevant effect on the pharmacokinetics of sitagliptin, metformin, and glimepiride.</p><p>&nbsp;</p><p>Coadministration of simvastatin with ertugliflozin resulted in a 24% and 19% increase in AUC and Cmax&nbsp;of simvastatin, respectively, and 30% and 16% increase in AUC and Cmax&nbsp;of simvastatin acid, respectively. The mechanism for the small increases in simvastatin and simvastatin acid is unknown and is not perpetrated through OATP inhibition by ertugliflozin. These increases are not considered to be clinically meaningful.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited data from the use of ertugliflozin in pregnant women. Based on results from animal studies, ertugliflozin may affect renal development and maturation (see section 5.3). Therefore, Steglatro should not be used during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is no information regarding the presence of ertugliflozin in human milk, the effects on the</p><p>breast-fed infant, or the effects on milk production. Ertugliflozin is present in the milk of lactating rats</p><p>&nbsp;</p><p>and caused effects in the offspring of lactating rats. Pharmacologically-mediated effects were observed in juvenile rats (see section 5.3). Since human kidney maturation occurs in utero and during the first</p><p>2 years of life when exposure from breast-feeding may occur, a risk to newborns/infants cannot be excluded. Steglatro should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>The effect of ertugliflozin on fertility in humans has not been studied. No effects on fertility were observed in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ertugliflozin has no or negligible influence on the ability to drive and use machines. Patients should be alerted to the risk of hypoglycaemia when Steglatro is used in combination with insulin or an insulin secretagogue and to the elevated risk of adverse reactions related to volume depletion, such as postural dizziness (see sections 4.2, 4.4, and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p><em>Pool</em><em> of placebo-controlled trials evaluating Steglatro 5 mg and 15 mg</em></p><p>The primary assessment of safety was conducted in a pool of three 26-week, placebo-controlled trials.</p><p>Ertugliflozin was used as monotherapy in one trial and as add-on therapy in two trials (see section 5.1). These data reflect exposure of 1,029 patients to ertugliflozin with a mean exposure</p><p>duration of approximately 25 weeks. Patients received ertugliflozin 5 mg (N=519), ertugliflozin 15 mg (N=510), or placebo (N=515) once daily.</p><p>&nbsp;</p><p>The most commonly reported adverse reactions across the clinical program were vulvovaginal mycotic infection and other female genital mycotic infections. Serious diabetic ketoacidosis occurred rarely.</p><p>See &ldquo;Description of selected adverse reactions&rdquo; for frequencies and see section 4.4.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions listed below are classified according to frequency and system organ class (SOC). Frequency categories are defined according to the following convention: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 1: Adverse reactions</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p><p>Frequency</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Adverse Reaction</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Vulvovaginal mycotic infection and other female genital mycotic infections*,&dagger;</p><p><strong>&nbsp;</strong></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Balanitis candida and other male genital mycotic infections*,&dagger;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p><p><strong>&nbsp;</strong></p><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Hypoglycaemia*,&dagger;</p><p><strong>&nbsp;</strong></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Diabetic ketoacidosis*,&dagger;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Volume depletion*,&dagger;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common Uncommon</p></td><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Increased urination&Dagger;</p><p><strong>&nbsp;</strong></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dysuria, Blood creatinine increased/Glomerular filtration rate decreased&dagger;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Vulvovaginal pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and</strong><strong> administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Thirst&sect;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Serum lipids changed&para;, Haemoglobin increased**, BUN increased&para;&para;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>*&nbsp;&nbsp; &nbsp;See Section 4.4.</p><p>&dagger;&nbsp;&nbsp; &nbsp;See subsections below for additional information.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;Includes: pollakiuria, micturition urgency, polyuria, urine output increased, and nocturia.</p><p>&sect;&nbsp;&nbsp; &nbsp;Includes: thirst and polydipsia.</p><p>&para;&nbsp;&nbsp; &nbsp;Mean percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were LDL-C 5.8% and 8.4% versus 3.2%; total cholesterol 2.8% and 5.7% versus 1.1%; however, HDL-C 6.2% and 7.6% versus 1.9%. Median</p><p>percent changes from baseline for ertugliflozin 5 mg and 15 mg versus placebo, respectively, were triglycerides -3.9% and -1.7% versus 4.5%.</p><p>** &nbsp;The proportion of subjects having at least 1 increase in haemoglobin &gt; 2.0 g/dL was higher in the ertugliflozin 5 mg and 15 mg groups (4.7% and 4.1%, respectively) compared to the placebo group (0.6%).</p><p>&para;&para;&nbsp;&nbsp;The proportion of subjects having any occurrence of BUN values &ge; 50% increase and value &gt;ULN was numerically higher in the ertugliflozin 5 mg group and higher in the 15 mg group (7.9% and 9.8%, respectively) relative to the placebo group (5.1%).</p><p>&nbsp;</p><p><em><u>Volume depletion</u></em></p><p>Ertugliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion. In the pool of placebo-controlled studies, the incidence of adverse events related to volume depletion (dehydration, dizziness postural, presyncope, syncope, hypotension, and orthostatic hypotension) was low (&lt; 2%) and not notably different across the ertugliflozin and placebo groups. In the subgroup analyses in the broader pool of Phase 3 studies, subjects with eGFR &lt; 60 mL/min/1.73 m2, subjects &ge; 65 years of age and subjects on diuretics had a higher incidence of volume depletion in the ertugliflozin groups relative to the comparator group (see sections 4.2 and 4.4). In subjects with eGFR &lt; 60 mL/min/1.73 m2, the incidence was 5.1%, 2.6%, and 0.5% for ertugliflozin 5 mg, ertugliflozin 15 mg, and the comparator group and for subjects with</p><p>eGFR 45 to &lt; 60 mL/min/1.73 m2, the incidence was 6.4%, 3.7%, and 0% respectively.</p><p>&nbsp;</p><p><em><u>Hypoglycaemia</u></em></p><p>In the pool of placebo-controlled studies, the incidence of documented hypoglycaemia was increased for ertugliflozin 5 mg and 15 mg (5.0% and 4.5%) compared to placebo (2.9%). In this population, the incidence of severe hypoglycaemia was 0.4% in each group. When ertugliflozin was used as monotherapy, the incidence of hypoglycaemic events in the ertugliflozin groups was 2.6% in both groups and 0.7% in the placebo group. When used as add-on to metformin, the incidence of hypoglycaemic events was 7.2% in the ertugliflozin 5 mg group, 7.8% in the ertugliflozin 15 mg</p><p>group and 4.3% in the placebo group.</p><p>&nbsp;</p><p>When ertugliflozin was added to metformin and compared to sulphonylurea, the incidence of hypoglycaemia was higher for the sulphonylurea (27%) compared to ertugliflozin (5.6% and 8.2% for ertugliflozin 5 mg and 15 mg, respectively).</p><p>&nbsp;</p><p>In patients with moderate renal impairment taking insulins, SU, or meglitinides as background medication, documented hypoglycaemia was 36%, 27% and 36% for ertugliflozin 5 mg, ertugliflozin</p><p>15 mg, and placebo, respectively (see sections 4.2, 4.4, and 4.5).</p><p>&nbsp;</p><p><em><u>Diabetic ketoacidosis</u></em></p><p>Across the clinical program, ketoacidosis was identified in 3 of 3,409 (0.1%) ertugliflozin-treated patients and 0.0% of comparator-treated patients (see section 4.4).</p><p>&nbsp;</p><p><em><u>Blood creatinine </u></em><em><u>increased/Glomerular</u></em><em><u> filtration rate decreased and renal-related events</u></em></p><p>Initial increases in mean creatinine and decreases in mean eGFR in patients treated with ertugliflozin were generally transient during continuous treatment. Patients with moderate renal impairment at baseline had larger mean changes that did not return to baseline at Week 26; these changes reversed after treatment discontinuation.</p><p>&nbsp;</p><p>Renal-related adverse reactions (e.g., acute kidney injury, renal impairment, acute prerenal failure) may occur in patients treated with ertugliflozin, particularly in patients with moderate renal impairment where the incidence of renal-related adverse reactions was 2.5%, 1.3%, and 0.6% in patients treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively.</p><p>&nbsp;</p><p><em><u>Genital mycotic infections</u></em></p><p>In the pool of three placebo-controlled clinical trials, female genital mycotic infections (e.g., genital candidiasis, genital infection fungal, vaginal infection, vulvitis, vulvovaginal candidiasis, vulvovaginal mycotic infection, vulvovaginitis) occurred in 9.1%, 12%, and 3.0% of females treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively. In females, discontinuation due to genital mycotic infections occurred in 0.6% and 0% of patients treated with ertugliflozin and placebo, respectively (see section 4.4)<em>.</em></p><p><em>&nbsp;</em></p><p>In the same pool, male genital mycotic infections (e.g., balanitis candida, balanoposthitis, genital infection, genital infection fungal) occurred in 3.7%, 4.2%, and 0.4% of males treated with ertugliflozin 5 mg, ertugliflozin 15 mg, and placebo, respectively. Male genital mycotic infections occurred more commonly in uncircumcised males. In males, discontinuations due to genital mycotic infections occurred in 0.2% and 0% of patients treated with ertugliflozin and placebo, respectively. In rare instances, phimosis was reported and sometimes circumcision was performed (see section 4.4).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ertugliflozin did not show any toxicity in healthy subjects at single oral doses up to 300 mg and multiple doses up to 100 mg daily for 2 weeks. No potential acute symptoms and signs of overdose were identified.</p><p>&nbsp;</p><p>In the event of an overdose, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient&rsquo;s clinical status. Removal of ertugliflozin by haemodialysis has not been studied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, Sodium glucose co-transporter 2 (SGLT2) inhibitors, ATC code: A10BK04.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is a potent, selective, and reversible inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>Urinary</em><em> glucose excretion and urinary volume</em></p><p>Dose-dependent increases in the amount of glucose excreted in urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following single- and multiple-dose administration of ertugliflozin. Dose-response modelling indicates that ertugliflozin 5 mg and 15 mg result in near maximal urinary glucose excretion (UGE) in patients with type 2 diabetes mellitus, providing 87% and 96% of maximal inhibition, respectively.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy and safety of ertugliflozin have been studied in 7 multi-centre, randomised, double-blind, placebo- or active comparator-controlled, Phase 3 clinical studies involving 4,863 patients with type 2 diabetes, including a study of 468 patients with moderate renal impairment. The racial distribution was 76.8% White, 13.3% Asian, 5.0% Black and 4.8% other. Hispanic or Latino patients comprised 24.2% of the population. Patients had an average age of 57.8 years (range 21 years to 87 years), with 25.8%</p><p>of patients &ge; 65 years of age and 4.5% &ge; 75 years of age.</p><p>&nbsp;</p><p>Ertugliflozin has been studied as monotherapy and in combination with metformin and/or a dipeptidyl peptidase 4 (DPP-4) inhibitor. Ertugliflozin has also been studied in combination with current diabetes treatments, including insulin and a sulphonylurea, in patients with type 2 diabetes with moderate renal impairment.</p><p>&nbsp;</p><p><em>Monotherapy</em></p><p>A total of 461 patients with type 2 diabetes inadequately controlled on diet and exercise participated in a randomised, double-blind, multi-centre, 26-week, placebo-controlled study to evaluate the efficacy and safety of ertugliflozin monotherapy. These patients, who were not receiving any background anti- hyperglycaemic treatment, were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily (see Table 2).</p><p>&nbsp;</p><p>Table 2: Results at Week 26 from a placebo-controlled monotherapy study of Steglatro*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Steglatro 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro 15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c</strong><strong> (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 151</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.2</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>8.1</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>-1.0</p></td><td rowspan="2" style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-1.0&Dagger; (-1.2, -0.8)</p></td><td style="vertical-align:top"><p>-1.2&Dagger; (-1.4, -0.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>44 (28.2)&sect;</p></td><td style="vertical-align:top"><p>54 (35.8)&sect;</p></td><td style="vertical-align:top"><p>20 (13.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 152</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>94.0</p></td><td style="vertical-align:top"><p>90.6</p></td><td style="vertical-align:top"><p>94.2</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.2</p></td><td style="vertical-align:top"><p>-3.6</p></td><td rowspan="2" style="vertical-align:top"><p>-1.4</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-1.8&Dagger; (-2.6, -0.9)</p></td><td style="vertical-align:top"><p>-2.2&Dagger; (-3.0, -1.3)</p></td></tr></tbody></table><p>* &nbsp;N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares means adjusted for treatment, time, prior antihyperglycaemic medication, baseline eGFR and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p&lt; 0.001 compared to placebo.</p><p>&sect;&nbsp;&nbsp; &nbsp;p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values)</p><p>&nbsp;</p><p><em>Ertugliflozin as add-on combination therapy with metformin</em></p><p>A total of 621 patients with type 2 diabetes inadequately controlled on metformin monotherapy (&ge; 1,500 mg/day) participated in a randomised, double-blind, multi-centre, 26-week, placebo-</p><p>controlled study to evaluate the efficacy and safety of ertugliflozin in combination with metformin. Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin therapy (see Table 3)</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 3: Results at Week 26 from a placebo-controlled study for Steglatro used in combination with metformin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Steglatro 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro 15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 207</strong></p></td><td style="vertical-align:top"><p><strong>N = 205</strong></p></td><td style="vertical-align:top"><p><strong>N = 209</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.2</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.7</p></td><td style="vertical-align:top"><p>-0.9</p></td><td rowspan="2" style="vertical-align:top"><p>-0.0</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-0.7&Dagger; (-0.9, -0.5)</p></td><td style="vertical-align:top"><p>-0.9&Dagger; (-1.1, -0.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients</strong><strong> [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>73 (35.3)&sect;</p></td><td style="vertical-align:top"><p>82 (40.0)&sect;</p></td><td style="vertical-align:top"><p>33 (15.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 207</strong></p></td><td style="vertical-align:top"><p><strong>N = 205</strong></p></td><td style="vertical-align:top"><p><strong>N = 209</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>84.9</p></td><td style="vertical-align:top"><p>85.3</p></td><td style="vertical-align:top"><p>84.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>-2.9</p></td><td rowspan="2" style="vertical-align:top"><p>-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-1.7&Dagger; (-2.2, -1.1)</p></td><td style="vertical-align:top"><p>-1.6&Dagger; (-2.2, -1.0)</p></td></tr></tbody></table><p>* &nbsp;N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp; &nbsp;Least squares means adjusted for treatment, time, prior antihyperglycemic medication, baseline eGFR, menopausal status randomization stratum, and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp; &nbsp;p&pound; 0.001 compared to placebo.</p><p>&sect;&nbsp;&nbsp; &nbsp;p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Active-controlled study</em><em> of ertugliflozin versus glimepiride as add-on combination therapy with metformin</em></p><p>A total of 1,326 patients with type 2 diabetes inadequately controlled on metformin monotherapy participated in a randomised, double-blind, multi-centre, 52-week, active comparator-controlled study to evaluate the efficacy and safety of ertugliflozin in combination with metformin. These patients, who were receiving metformin monotherapy (&ge; 1,500 mg/day), were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or glimepiride administered once daily in addition to continuation of background metformin therapy. Glimepiride was initiated at 1 mg/day and titrated up to a maximum dose of 6 or</p><p>8 mg/day (depending on maximum approved dose in each country) or a maximum tolerated dose or down-titrated to avoid or manage hypoglycaemia. The mean daily dose of glimepiride was 3.0 mg (see Table 4).</p><p>&nbsp;</p><p>Table 4: Results at Week 52 from an active-controlled study comparing Steglatro to glimepiride as add-on therapy in patients inadequately controlled on metformin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Steglatro 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro 15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Glimepiride</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 448</strong></p></td><td style="vertical-align:top"><p><strong>N = 440</strong></p></td><td style="vertical-align:top"><p><strong>N = 437</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>7.8</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>-0.6</p></td><td rowspan="2" style="vertical-align:top"><p>-0.7</p></td></tr><tr><td style="vertical-align:top"><p>Difference from glimepiride (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>0.2 (0.1, 0.3)</p></td><td style="vertical-align:top"><p>0.1&Dagger; (-0.0, 0.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>154 (34.4)</p></td><td style="vertical-align:top"><p>167 (38.0)</p></td><td style="vertical-align:top"><p>190 (43.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 448</strong></p></td><td style="vertical-align:top"><p><strong>N = 440</strong></p></td><td style="vertical-align:top"><p><strong>N = 437</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>87.9</p></td><td style="vertical-align:top"><p>85.6</p></td><td style="vertical-align:top"><p>86.8</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>-3.4</p></td><td rowspan="2" style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from glimepiride (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-3.9 (-4.4, -3.4)</p></td><td style="vertical-align:top"><p>-4.3&sect; (-4.8, -3.8)</p></td></tr></tbody></table><p>*&nbsp; N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, prior antihyperglycemic medication, baseline eGFR&nbsp; and the interaction of time by treatment.</p><p>&Dagger;&nbsp; &nbsp;Non-inferiority is declared when the upper bound of the two-sided 95% confidence interval (CI) for the mean difference is less than 0.3%.</p><p>&sect;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to glimepiride.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Factorial study with ertugliflozin</em><em> and sitagliptin as add-on combination therapy with metformin</em></p><p>A total of 1,233 patients with type 2 diabetes participated in a randomised, double-blind, multi-centre, 26-week, active-controlled study to evaluate the efficacy and safety of ertugliflozin 5 mg or 15 mg in combination with sitagliptin 100 mg compared to the individual components. Patients with type 2 diabetes inadequately controlled on metformin monotherapy (&ge; 1,500 mg/day) were randomised to one of five active-treatment arms: ertugliflozin 5 mg or 15 mg, sitagliptin 100 mg, or sitagliptin 100 mg in combination with 5 mg or 15 mg ertugliflozin administered once daily in addition to continuation of background metformin therapy (see Table 5).</p><p>&nbsp;</p><p>Table 5: Results at Week 26 from a factorial study with Steglatro and sitagliptin as add-on combination therapy with metformin compared to individual components alone*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Steglatro 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro 15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Sitagliptin</strong><strong> </strong><strong>100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro 5 mg + Sitagliptin 100 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro 15 mg + Sitagliptin 100 mg</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p><p><strong>&nbsp;</strong></p><p>Baseline (mean)</p><p>Change from baseline (LS mean&dagger;) Difference from</p><p>Sitagliptin Steglatro 5 mg</p><p>Steglatro 15 mg (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p><strong>N = 250</strong></p><p><strong>&nbsp;</strong></p><p>8.6</p><p><strong>&nbsp;</strong></p><p>-1.0</p></td><td style="vertical-align:top"><p><strong>N = 248</strong></p><p><strong>&nbsp;</strong></p><p>8.6</p><p><strong>&nbsp;</strong></p><p>-1.1</p></td><td style="vertical-align:top"><p><strong>N = 247</strong></p><p><strong>&nbsp;</strong></p><p>8.5</p><p><strong>&nbsp;</strong></p><p>-1.1</p></td><td style="vertical-align:top"><p><strong>N = 243</strong></p><p><strong>&nbsp;</strong></p><p>8.6</p><p><strong>&nbsp;</strong></p><p>-1.5</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>-0.4&Dagger; (-0.6, -0.3)</p><p>-0.5&Dagger; (-0.6, -0.3)</p></td><td style="vertical-align:top"><p><strong>N = 244</strong></p><p><strong>&nbsp;</strong></p><p>8.6</p><p><strong>&nbsp;</strong></p><p>-1.5</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>-0.5&Dagger; (-0.6, -0.3)</p><p><strong>&nbsp;</strong></p><p>-0.4&Dagger; (-0.6, -0.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>66 (26.4)</p></td><td style="vertical-align:top"><p>79 (31.9)</p></td><td style="vertical-align:top"><p>81 (32.8)</p></td><td style="vertical-align:top"><p>127&sect; (52.3)</p></td><td style="vertical-align:top"><p>120&sect; (49.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 250</strong></p></td><td style="vertical-align:top"><p><strong>N = 248</strong></p></td><td style="vertical-align:top"><p><strong>N = 247</strong></p></td><td style="vertical-align:top"><p><strong>N = 243</strong></p></td><td style="vertical-align:top"><p><strong>N = 244</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>88.6</p></td><td style="vertical-align:top"><p>88.0</p></td><td style="vertical-align:top"><p>89.8</p></td><td style="vertical-align:top"><p>89.5</p></td><td style="vertical-align:top"><p>87.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td rowspan="3" style="vertical-align:top"><p>-2.7</p></td><td rowspan="3" style="vertical-align:top"><p>-3.7</p></td><td rowspan="3" style="vertical-align:top"><p>-0.7</p></td><td style="vertical-align:top"><p>-2.5</p></td><td style="vertical-align:top"><p>-2.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from Sitagliptin</p></td><td rowspan="2" style="vertical-align:top"><p>-1.8&Dagger; (-2.5, -1.2)</p></td><td rowspan="2" style="vertical-align:top"><p>-2.3&Dagger; (-2.9, -1.6)</p></td></tr><tr><td style="vertical-align:top"><p>(LS mean&dagger;, 95% CI)</p></td></tr></tbody></table><p>*&nbsp;&nbsp; &nbsp;N includes all randomised, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, baseline eGFR and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to control group.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to corresponding dose of ertugliflozin or sitagliptin (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Ertugliflozin as add-on combination therapy with metformin and sitagliptin</em></p><p>A total of 463 patients with type 2 diabetes inadequately controlled on metformin (&ge; 1,500 mg/day) and sitagliptin 100 mg once daily participated in a randomised, double-blind, multi-centre, 26-week, placebo-controlled study to evaluate the efficacy and safety of ertugliflozin. Patients were randomised to ertugliflozin 5 mg, ertugliflozin 15 mg, or placebo administered once daily in addition to continuation of background metformin and sitagliptin therapy (see Table 6).</p><p>&nbsp;</p><p>Table 6: Results at Week 26 from an add-on study of Steglatro in combination with metformin and sitagliptin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Steglatro</strong><strong> 5 mg</strong></p></td><td style="vertical-align:top"><p><strong>Steglatro</strong><strong> 15 mg</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>8.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>-0.9</p></td><td rowspan="2" style="vertical-align:top"><p>-0.1</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-0.7&Dagger; (-0.9, -0.5)</p></td><td style="vertical-align:top"><p>-0.8&Dagger; (-0.9, -0.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt; 7%</strong></p></td><td style="vertical-align:top"><p>50 (32.1)&sect;</p></td><td style="vertical-align:top"><p>61 (39.9)&sect;</p></td><td style="vertical-align:top"><p>26 (17.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 156</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td><td style="vertical-align:top"><p><strong>N = 153</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>87.6</p></td><td style="vertical-align:top"><p>86.6</p></td><td style="vertical-align:top"><p>86.5</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-3.3</p></td><td style="vertical-align:top"><p>-3.0</p></td><td rowspan="2" style="vertical-align:top"><p>-1.3</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-2.0&Dagger; (-2.6, -1.4)</p></td><td style="vertical-align:top"><p>-1.7&Dagger; (-2.3, -1.1)</p></td></tr></tbody></table><p>*&nbsp; N includes all randomized, treated patients who had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp; Least squares means adjusted for treatment, time, prior antihyperglycaemic medication, baseline eGFR, and the interaction of time by treatment.</p><p>&Dagger;&nbsp; p&lt; 0.001 compared to placebo.</p><p>&sect;&nbsp;&nbsp; &nbsp;p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p><em>Combination</em><em> </em><em>therapy of ertugliflozin</em><em> and sitagliptin</em></p><p>A total of 291 patients with type 2 diabetes inadequately controlled on diet and exercise participated in a randomised, double-blind, multi-centre, placebo-controlled 26-week study to evaluate the efficacy and safety of ertugliflozin in combination with sitagliptin. These patients, who were not receiving any background anti-hyperglycaemic treatment, were randomised to ertugliflozin 5 mg or ertugliflozin</p><p>15 mg in combination with sitagliptin (100 mg) or to placebo once daily (see Table 7).</p><p>&nbsp;</p><p>Table 7: Results at Week-26 from a combination therapy study of ertugliflozin and sitagliptin*</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Ertugliflozin </strong><strong>5 mg</strong></p><p><strong>+ Sitagliptin</strong></p></td><td style="vertical-align:top"><p><strong>Ertugliflozin</strong><strong> </strong><strong>15 mg</strong></p><p><strong>+ Sitagliptin</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HbA1c (%)</strong></p></td><td style="vertical-align:top"><p><strong>N = 98</strong></p></td><td style="vertical-align:top"><p><strong>N = 96</strong></p></td><td style="vertical-align:top"><p><strong>N = 96</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>9.0</p></td><td style="vertical-align:top"><p>9.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-1.6</p></td><td style="vertical-align:top"><p>-1.7</p></td><td style="vertical-align:top"><p>-0.4</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger; and 95% CI)</p></td><td style="vertical-align:top"><p>-1.2&Dagger; (-1.5, -0.8)</p></td><td style="vertical-align:top"><p>-1.2&Dagger; (-1.6, -0.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients [N (%)] with HbA1c &lt;7%</strong></p></td><td style="vertical-align:top"><p>35 (35.7)&sect;</p></td><td style="vertical-align:top"><p>30 (31.3)&sect;</p></td><td style="vertical-align:top"><p>8 (8.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body Weight (kg)</strong></p></td><td style="vertical-align:top"><p><strong>N = 98</strong></p></td><td style="vertical-align:top"><p><strong>N = 96</strong></p></td><td style="vertical-align:top"><p><strong>N = 97</strong></p></td></tr><tr><td style="vertical-align:top"><p>Baseline (mean)</p></td><td style="vertical-align:top"><p>90.8</p></td><td style="vertical-align:top"><p>91.3</p></td><td style="vertical-align:top"><p>95.0</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline (LS mean&dagger;)</p></td><td style="vertical-align:top"><p>-2.9</p></td><td style="vertical-align:top"><p>-3.0</p></td><td style="vertical-align:top"><p>-0.9</p></td></tr><tr><td style="vertical-align:top"><p>Difference from placebo (LS mean&dagger;, 95% CI)</p></td><td style="vertical-align:top"><p>-2.0&Dagger; (-3.0, -1.0)</p></td><td style="vertical-align:top"><p>-2.1&Dagger; (-3.1, -1.1)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*&nbsp; N includes all patients who received at least one dose of study medication and had at least one measurement of the outcome variable.</p><p>&dagger;&nbsp;&nbsp;&nbsp; Least squares means adjusted for treatment, time, antihyperglycemic medication wash-off status, baseline eGFR, and the interaction of time by treatment.</p><p>&Dagger;&nbsp;&nbsp;&nbsp; p&lt; 0.001 compared to placebo.</p><p>&sect; p&lt; 0.001 compared to placebo (based on adjusted odds ratio comparisons from a logistic regression model using multiple imputation for missing data values).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Moderate renal</em><em> </em><em>impairment</em></p><p>The efficacy of ertugliflozin was also assessed separately in a dedicated study of diabetic patients with moderate renal impairment (468 patients with eGFR &ge; 30 to &lt; 60 ml/min/1.73 m2).</p><p>&nbsp;</p><p>The LS mean (95% CI) changes from baseline in HbA1c were -0.26 (-0.42, -0.11), -0.29</p><p>(-0.44, -0.14), and -0.41 (-0.56, -0.27) in the placebo, ertugliflozin 5 mg, and ertugliflozin 15 mg</p><p>&nbsp;</p><p>groups, respectively. The HbA1c reductions in the ertugliflozin arms were not significantly different from placebo. The pre-specified analysis of glycaemic efficacy was confounded by use of a prohibited concomitant antihyperglycaemic medication. In a subsequent analysis excluding those subjects who used the prohibited medication, ertugliflozin 5 mg and 15 mg were associated with placebo-corrected reductions in HbA1c of -0.14 (-0.36, 0.08) and -0.33 (-0.55, -0.11)</p><p>&nbsp;</p><p><em>Fasting</em><em> plasma glucose</em></p><p>In three placebo-controlled studies, ertugliflozin resulted in statistically significant reductions in FPG. For ertugliflozin 5 mg and 15 mg, respectively, the placebo-corrected reductions in FPG were 1.92 and</p><p>2.44 mmol/l as monotherapy, 1.48 and 2.12 mmol/l as add-on to metformin, and 1.40 and 1.74 mmol/l as add-on to metformin and sitagliptin.</p><p>&nbsp;</p><p>The combination of ertugliflozin and sitagliptin resulted in significantly greater reductions in FPG compared to sitagliptin or ertugliflozin alone or placebo. The combination of ertugliflozin 5 or 15 mg and sitagliptin resulted in incremental FPG reductions of 0.46 to 0.65 mmol/l compared to the ertugliflozin alone or 1.02 to 1.28 mmol/l compared to sitagliptin alone. The placebo-corrected reductions of ertugliflozin 5 or 15 mg in combination with sitagliptin were 2.16 and 2.56 mmol/l.</p><p>&nbsp;</p><p><em>Efficacy in patients with baseline</em><em> HbA1c</em><em> &ge; 8%</em></p><p>In the monotherapy study conducted on a background of diet and exercise in patients with baseline HbA1c from 7-10.5%, the subgroup of patients in the study with a baseline HbA1c &ge; 8% had placebo-corrected reductions in HbA1c of 1.11% and 1.52% with ertugliflozin 5 or 15 mg, respectively.</p><p>&nbsp;</p><p>In the study of ertugliflozin added-on to metformin in patients with baseline HbA1c from 7.0-10.5%, the placebo-corrected reductions in HbA1c for the subgroup of patients in the study with baseline HbA1c &ge; 9% were 1.31% and 1.43% with ertugliflozin 5 and 15 mg, respectively.</p><p>&nbsp;</p><p>In the study of patients inadequately controlled on metformin with baseline HbA1c from 7.5-11.0%, among the subgroup of patients with a baseline HbA1c &ge; 10%, the combination of ertugliflozin 5 mg or 15 mg with sitagliptin resulted in reductions of HbA1c of 2.35% and 2.66% compared to 2.10%, 1.30%, and 1.82% for ertugliflozin 5 mg, ertugliflozin 15 mg and sitagliptin alone, respectively.</p><p>&nbsp;</p><p><em>Post-prandial glucose</em></p><p>In the monotherapy study, ertugliflozin 5 and 15 mg resulted in statistically significant placebo- corrected reductions in 2-hour PPG of 3.83 and 3.74 mmol/l.</p><p>&nbsp;</p><p><em>Blood pressure</em></p><p>In three 26-week, placebo-controlled studies, ertugliflozin reduced systolic blood pressure (SBP). For ertugliflozin 5 mg and 15 mg, the statistically significant placebo-corrected reductions in SBP ranged from 2.9 mmHg to 3.7 mmHg and 1.7 mmHg to 4.5 mmHg, respectively.</p><p>&nbsp;</p><p>In a 52-week, active-controlled study versus glimepiride, reductions from baseline in SBP were</p><p>2.2 mmHg and 3.8 mmHg for ertugliflozin 5 mg and 15 mg respectively, while subjects treated with glimepiride had an increase in SBP from baseline of 1.0 mmHg.</p><p>&nbsp;</p><p><em>Subgroup analysis</em></p><p>In patients with type 2 diabetes treated with ertugliflozin, clinically meaningful reductions in HbA1c were observed in subgroups defined by age, sex, race, ethnicity, geographic region, baseline BMI, baseline HbA1c, and duration of type 2 diabetes mellitus.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with ertugliflozin in one or more subsets of the paediatric population in Type II diabetes mellitus (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General introduction</u></p><p>The pharmacokinetics of ertugliflozin are similar in healthy subjects and patients with type 2 diabetes. The steady state mean plasma AUC and Cmax were 398 ng∙hr/ml and 81 ng/ml, respectively, with 5 mg ertugliflozin once daily treatment, and 1,193 ng∙hr/ml and 268 ng/ml, respectively, with 15 mg ertugliflozin once daily treatment. Steady-state is reached after 4 to 6 days of once-daily dosing with ertugliflozin. Ertugliflozin does not exhibit time-dependent pharmacokinetics and accumulates in plasma up to 10-40% following multiple dosing.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Following single-dose oral administration of 5 mg and 15 mg of ertugliflozin, peak plasma concentrations (median Tmax) of ertugliflozin occur at 1 hour postdose under fasted conditions. Plasma Cmax&nbsp;and AUC of ertugliflozin increase in a dose-proportional manner following single doses from</p><p>0.5 mg to 300 mg and following multiple doses from 1 mg to 100 mg. The absolute oral bioavailability of ertugliflozin following administration of a 15-mg dose is approximately 100%.</p><p>&nbsp;</p><p>Administration of ertugliflozin with a high-fat and high-calorie meal decreases ertugliflozin Cmax&nbsp;by 29% and prolongs Tmax&nbsp;by 1 hour, but does not alter AUC as compared with the fasted state. The observed effect of food on ertugliflozin pharmacokinetics is not considered clinically relevant, and ertugliflozin may be administered with or without food. In Phase 3 clinical trials, ertugliflozin was administered without regard to meals.</p><p>&nbsp;</p><p>Ertugliflozin is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The mean steady-state volume of distribution of ertugliflozin following an intravenous dose is 86 l. Plasma protein binding of ertugliflozin is 93.6% and is independent of ertugliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment. The blood-to-plasma concentration ratio of ertugliflozin is 0.66.</p><p>&nbsp;</p><p>Ertugliflozin is not a substrate of organic anion transporters (OAT1, OAT3), organic cation transporters (OCT1, OCT2), or organic anion transporting polypeptides (OATP1B1, OATP1B3) <em>in vitro.</em></p><p><em>&nbsp;</em></p><p><u>Biotransformation</u></p><p>Metabolism is the primary clearance mechanism for ertugliflozin. The major metabolic pathway for ertugliflozin is UGT1A9 and UGT2B7-mediated O-glucuronidation to two glucuronides that are pharmacologically inactive at clinically relevant concentrations. CYP-mediated (oxidative) metabolism of ertugliflozin is minimal (12%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The mean systemic plasma clearance following an intravenous 100 &micro;g dose was 11 l/hr. The mean elimination half-life in type 2 diabetic patients with normal renal function was estimated to be</p><p>17 hours based on the population pharmacokinetic analysis. Following administration of an oral [14C]-ertugliflozin solution to healthy subjects, approximately 41% and 50% of the drug-related</p><p>radioactivity was eliminated in faeces and urine, respectively. Only 1.5% of the administered dose was excreted as unchanged ertugliflozin in urine and 34% as unchanged ertugliflozin in faeces, which is likely due to biliary excretion of glucuronide metabolites and subsequent hydrolysis to parent.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In a Phase 1 clinical pharmacology study in patients with type 2 diabetes and mild, moderate, or severe renal impairment (as determined by eGFR), following a single-dose administration of 15 mg ertugliflozin, the mean increases in AUC of ertugliflozin were &le; 1.7-fold, compared to subjects with</p><p>&nbsp;</p><p>normal renal function. These increases in ertugliflozin AUC are not considered clinically relevant. There were no clinically meaningful differences in the ertugliflozin Cmax&nbsp;values among the different renal function groups. The 24-hour urinary glucose excretion declined with increasing severity of renal impairment (see section 4.4). The plasma protein binding of ertugliflozin was unaffected in patients with renal impairment.</p><p>&nbsp;</p><p><em>Hepatic</em><em> impairment</em></p><p>Moderate hepatic impairment (based on the Child-Pugh classification) did not result in an increase in exposure of ertugliflozin. The AUC of ertugliflozin decreased by approximately 13%, and Cmax&nbsp;decreased by approximately 21% compared to subjects with normal hepatic function. This decrease in ertugliflozin exposure is not considered clinically meaningful. There is no clinical experience in patients with Child-Pugh class C (severe) hepatic impairment. The plasma protein binding of ertugliflozin was unaffected in patients with moderate hepatic impairment.</p><p>&nbsp;</p><p><em>Paediatric</em><em> population</em></p><p>No studies with ertugliflozin have been performed in paediatric patients.</p><p>&nbsp;</p><p><em>Effects of age, body weight, gender, and race</em></p><p>Based on a population pharmacokinetic analysis, age, body weight, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of ertugliflozin.</p><p>&nbsp;</p><p><u>Drug interactions</u></p><p>&nbsp;</p><p><u>In vitro <em>assessment of ertugliflozin</em></u></p><p>In <em>in vitro </em>studies, ertugliflozin and ertugliflozin glucuronides did not inhibit or inactivate CYPs 1A2, 2C9, 2C19, 2C8, 2B6, 2D6, or 3A4, and did not induce CYPs 1A2, 2B6, or 3A4. Ertugliflozin and ertugliflozin glucuronides did not inhibit the activity of UGTs 1A6, 1A9 or 2B7 <em>in</em><em> vitro</em>. Ertugliflozin was a weak inhibitor of UGTs 1A1 and 1A4 <em>in vitro </em>at higher concentrations that are not clinically relevant. Ertugliflozin glucuronides had no effect on these isoforms. Overall, ertugliflozin is unlikely to affect the pharmacokinetics of concurrently administered drugs eliminated by these enzymes.</p><p>&nbsp;</p><p>Ertugliflozin or ertugliflozin glucuronides do not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 transporters or transporting polypeptides OATP1B1 and OATP1B3 at clinically relevant concentrations <em>in vitro</em>. Overall, ertugliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are substrates of these transporters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, acute toxicity, repeated dose toxicity, genotoxicity, and carcinogenic potential.</p><p>&nbsp;</p><p><u>General toxicity</u></p><p>Repeat-dose oral toxicity studies were conducted in mice, rats, and dogs for up to 13, 26, and</p><p>39&nbsp; weeks, respectively. Signs of toxicity that were considered adverse were generally observed at exposures greater than or equal to 77 times the human unbound exposure (AUC) at the maximum recommended human dose (MRHD) of 15 mg/day. Most toxicity was consistent with pharmacology related to urinary glucose loss and included decreased body weight and body fat, increased food consumption, diarrhoea, dehydration, decreased serum glucose and increases in other serum parameters reflective of increased protein metabolism, gluconeogenesis and electrolyte imbalances, and urinary changes such as polyuria, glucosuria, and calciuria. Microscopic changes related to glucosuria and/or calciuria observed only in rodents included dilatation of renal tubules, hypertrophy of zona glomerulosa in adrenal glands (rats), and increased trabecular bone (rats). Except for emesis, there were no adverse toxicity findings in dogs at 379 times the human unbound exposure (AUC) at the MRHD of 15 mg/day.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>In the 2-year mouse carcinogenicity study, ertugliflozin was administered by oral gavage at doses of 5, 15, and 40 mg/kg/day. There were no ertugliflozin-related neoplastic findings at doses up to</p><p>40&nbsp; mg/kg/day (approximately 41 times human unbound exposure at the MRHD of 15 mg/day based on AUC). In the 2-year rat carcinogenicity study, ertugliflozin was administered by oral gavage at doses of 1.5, 5, and 15 mg/kg/day. Ertugliflozin-related neoplastic findings included an increased incidence of benign adrenal medullary pheochromocytoma in male rats at 15 mg/kg/day. This finding was attributed to carbohydrate malabsorption leading to altered calcium homeostasis and was not considered&nbsp;&nbsp; &nbsp;relevant to human risk. The no-observed-effect level (NOEL) for neoplasia was</p><p>5 mg/kg/day (approximately 16 times human unbound exposure at the MRHD of 15 mg/day).</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>Ertugliflozin was not mutagenic or clastogenic with or without metabolic activation in the microbial reverse mutation, <em>in vitro </em>cytogenetic (human lymphocytes), and <em>in vivo </em>rat micronucleus assays.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>In the rat fertility and embryonic development study, male and female rats were administered ertugliflozin at 5, 25, and 250 mg/kg/day. No effects on fertility were observed at 250 mg/kg/day (approximately 386 times human unbound exposure at the MRHD of 15 mg/day based on AUC comparisons). Ertugliflozin did not adversely affect developmental outcomes in rats and rabbits at maternal exposures that were 239 and 1,069 times, respectively, the human exposure at the maximum clinical dose of 15 mg/day, based on AUC. At a maternally toxic dose in rats (250 mg/kg/day), lower foetal viability and a higher incidence of a visceral malformation were observed at maternal exposure that was 510 times the maximum clinical dose of 15 mg/day.</p><p>&nbsp;</p><p>In the pre- and postnatal development study, decreased postnatal growth and development were observed in rats administered ertugliflozin gestation day 6 through lactation day 21 at</p><p>&ge; 100 mg/kg/day (estimated 239 times the human exposure at the maximum clinical dose of</p><p>15 mg/day, based on AUC). Sexual maturation was delayed in both sexes at 250 mg/kg/day (estimated 620 times the MRHD at 15 mg/day, based on AUC).</p><p>&nbsp;</p><p>When ertugliflozin was administered to juvenile rats from postnatal day (PND) 21 to PND 90, a period of renal development corresponding to the late second and third trimesters of human pregnancy, increased kidney weights, dilatation of the renal pelvis and tubules, and renal tubular mineralization were seen at an exposure 13 times the maximum clinical dose of 15 mg/day, based on AUC. Effects</p><p>on bone (shorter femur length, increased trabecular bone in the femur) as well as effects of delayed puberty were observed at an exposure 817 times the MRHD of 15 mg/day based on AUC. The effects on kidney and bone did not fully reverse after the 1-month recovery period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Microcrystalline cellulose (E460) Lactose monohydrate</p><p>Sodium starch glycolate (Type A) Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Film coating</u></p><p>Hypromellose 2910/6 (E464) Lactose monohydrate Macrogol 3350 (E1521) Triacetin (E1518)</p><p>Titanium dioxide (E171) Iron oxide red (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Store below 30&deg;C.&nbsp; Store in the original package</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/PVC/PA/Alu blisters<strong>.</strong></p><p>Packs of 14, 28, 30, 84, 90 and 98 film-coated tablets in non-perforated blisters. Packs of 30x1 film-coated tablets in perforated unit dose blisters.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder:
Merck Sharp & Dohme B.V.
Waarderweg 
2031 BN Haarlem 
The Netherlands

Manufacturer:
Pfizer Manufacturing Deutschland GmbH
Betriebsstatte, Freiburg
Mooswaldellee 1
79090
Freiburg, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>